Brandt Publications (Selected from 28)

1. "Behavioral effects and binding affinities of the fentanyl derivative OHM3507" C. P. France, S. C. Ahn, L. L. Brockunier, J. R. Bagley, M. R. Brandt, P. J. Winsauer, J. M. Moerschbaecher, Pharmacol. Biochem. Behav. 1998, 59, 295-303.
2. "Pharmacological profile of a deuterium-substituted mirfentanil derivative, OHM 10579, in rhesus monkeys" S. Lelas, L. R. Gerak, L. K. Landers, M. R. Brandt, J. R. Bagley, L. L. Brockunier, C. P. France, Pharmacol. Biochem. Behav. 1998, 60, 665-675.
3. "Chronic l-alpha-acetylmethadol (LAAM) in rhesus monkeys: Tolerance and cross-tolerance to the antinociceptive, ventilatory and rate-decreasing effects of opioids" M. R. Brandt, C. P. France, J. Pharmacol. Exp. Ther. 2000, 294, 166-178.
4. "Antinociceptive effects of delta-opioid agonists in rhesus monkeys: Effects on chemically-induced thermal hypersensitivity" M. R. Brandt, M. S. Furness, N. K. Mello, K. C. Rice, S. S. Negus, J. Pharmacol. Exp. Ther. 2001, 296, 939-946.
5. "Effects of nicotine and epibatidine on thermal nociception and prostaglandin E2-induced thermal hypersensitivity in rhesus monkeys" M. R. Brandt, S. S. Negus, Analgesia 2001, 5, 239-247.
6. "Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation" M. R. Brandt, B. D. Fisher, M. S. Furness, K. C. Rice, S. S. Negus,   J. Pharmacol. Exp. Ther. 2001, 299, 629-637.
7. "Current and emerging opportunities for the treatment of neuropathic pain" J. A. Butera, M. R. Brandt,   Annual Reports in Medicinal Chemistry 2003, 38, 1-10.
8. "Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazobicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid] on chemically-induced thermal hypersensitivity" M. R. Brandt, T. A. Cummons, L. Potestio, S. J. Sukoff, S. Rosenzweig-Lipson, S. J. Pharmacol. Exp. Ther. 2005, 313, 1379-1386.
9. "Neurochemical changes in the RVM associated with peripheral inflammatory pain stimuli" V. A. Smith, C. E. Beyer, C.E., M. R. Brandt, Brain Res. 2006, 1095, 65-72.
10. "Preclinical Assessment of Candidate Analgesic Drugs: Recent Advances and Future Challenges" S. S. Negus, T. W. Vanderah, M. R. Brandt, E. J. Bilsky, L. Becerra, D. Borsook, J. Pharmacol. Exp. Ther. 2006, 319, 507-514.
11. "An Estrogen Receptor-beta Agonist is active in Models of Inflammatory and Chemical-Induced Pain" L. Leventhal, M. R. Brandt, T. A. Cummons, M. J. Piesla, K. E. Rogers, H. A. Harris, Eur. J. Pharmacol. 2006, 553, 146-148.
12. "Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain"  L. Leventhal, V. A. Smith, G. Hornby, T. H. Andree, M. R. Brandt, K. E. Rogers, J. Pharmacol. Exp. Ther. 2007, 320, 1178-85.
13. "Attenuated cold sensation and neuropathy-induced cold allodynia in TRPM8 Null Mice" R. W. Colburn, M. -L. Lubin, D. J. Stone Jr., Y. Wang, D. Lawrence, M. R. D’Andrea, M. R. Brandt, Y. Liu, C. M. Flores, N. Qin, Neuron 2007, 54, 379-86.
14. "Discovery of piperidine carboxamide TRPV1 antagonists" W. S. Cheung, R. R. Calvo, B. A. Tounge, S. -P. Zhang, D. R. Stone, M. R. Brandt, T. Hutchinson, C. M. Flores, M. R. Player, Bioorg. Med. Chem. Lett.2008, 18, 4569-4572.
15. "Prodrugs of perzinfotel (EAA-090) with improved oral bioavailability" R. B. Baudy, J. A. Butera, M. A. Abou-Gharbia, H. Chen, B. Harrison, U. Jain, R. Magolda, J. Y. Sze, M. R. Brandt, T. A. Cummons, D. Kowal, M. N. Pangalos, B. Zupan, M. Hoffmann, M. May, C. Mugford, J. Kennedy, W. E. Childers Jr., J. Med. Chem. 2009, 52, 771-778.

Kinney Publications (Selected from 49)

1. “Bioisosteric replacement of the alpha-amino carboxylic acid functionality of 2-amino-5-phosphonopentanoic acid (AP5) yields unique 3,4-diamino-4-cyclobutene-1,2-dione Containing NMDA Antagonists"  W. A. Kinney, N. E. Lee, D. T. Garrison, E. J. Podlesney Jr., R. R. Notvest, J. T. Simmonds, D. Bramlett, D. M. Kowal, R. P. Tasse, J. Med. Chem. 1992, 35, 4720.
2. "Synthesis of Alkyl Substituted Cyclobutenediones by Free Radical Chemistry.  Carbon for Nitrogen Replacement in the alpha-Amino Acid Bioisostere - 1,2-Diamino-1-cyclobutene-3,4-dione"  W. A. Kinney Tetrahedron Lett. 1993, 2715-2718.
3. "Synthesis of 3-hydroxy-3-cyclobutene-1,2-dione based amino acids"  E. F. Campbell, A. K. Park, W. A. Kinney, R. W. Fengl, L. S. Liebeskind, J. Org. Chem. 1995, 60, 1470-1472.
4. "The 3-cyclobutene-1,2-dione group: versatile template for bioisostere construction" W. A. Kinney, Phosphorus, Sulfur, and Silicon 1996, 109-110, 305-308.
5. “Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature” A. K. Sills, Jr., J. I. Williams, B. M. Tyler, D. S. Epstein, E. P. Sipos, M. P. McLane, S. Pitchford, K. Cheshire, F. H. Gannon, W. A. Kinney, T. L. Chao, J. D. Davis, M. Donowitz, J. Laterra, M. Zasloff, H. Brem, Cancer Research 1998, 58, 2784-2792.
6. "Synthesis of squalamine utilizing a readily accessible spermidine equivalent” X. Zhang, M. N. Rao, S. R. Jones, B. Shao, P. Feibush, M. McGuigan, N. Tzodikov, B. Feibush, I. Sharkansky, B. Snyder, L. M. Mallis, A. Sarkahian, S. Wilder, J. E. Turse, W. A. Kinney, H. J. Kjaersgaard, R. S. Michalak, J. Org. Chem. 1998, 63, 8599-8603.
7. “Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]-phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere”  W. A. Kinney, M. Abou-Gharbia, D. T. Garrison, J. Schmid, D. M. Kowal, D. R. Bramlett, T. L. Miller, R. P. Tasse, M. M. Zaleska, J. A. Moyer, J. Med. Chem. 1998, 41, 236-246.
8. “A short formal synthesis of squalamine from a microbial metabolite” W. A. Kinney, X. Zhang, J. I. Williams, S. Johnston, R. S. Michalak, M. Deshpande, L. Dostal, J. P. N. Rosazza, Org. Lett. 2000, 2, 2921-2922.
9. “A spermine-coupled cholesterol metabolite from the shark with potent appetite suppressant and antidiabetic properties” M. Zasloff, J. I. Williams, Q. Chen, M. Anderson, T. Maeder, K. Holroyd, S. Jones, W. A. Kinney, K. R. Cheshire, Int. J. Obesity 2001, 25, 689-697.
10. “Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model” W. A. Kinney, H. R. Almond, Jr., J. Qi, C. E. Smith, R. J. Santulli, L. de Garavilla, P. Andrade-Gordon, D. S. Cho, A. M. Everson, M. A. Feinstein, P. A. Leung, B. E. Maryanoff, Angewandte Chemie, Int. Ed. 2002, 41, 2940-2944. 
11. “1,2,3,4-Tetrahydroquinoline-containing alpha-V beta-3 integrin antagonists with enhanced oral bioavailability” S. Ghosh, R. J. Santulli, W. A. Kinney, B. L DeCorte, L. Liu, J. M. Lewis, J. C. Proost, G. C. Leo, J. Masucci, W. E. Hageman, A. S. Thompson, I. Chen, R. Kawahama, R. W Tuman, R. A. Galemmo, Jr., D. L. Johnson, B. P. Damiano, B. E. Maryanoff, Bioorg. Med. Chem. Lett. 2004, 14, 5937-5941.
    
12. “Collagen-related peptides: self-assembly of short, single strands into a functional Biomaterial of Micrometer Scale” M. A. Cejas, W. A. Kinney, C. Chen, G. C. Leo, B. A. Tounge, J. G. Vinter, P. P. Joshi, B. E. Maryanoff, J. Am. Chem. Soc. 2007, 129, 2202-2203.
13. “Suzuki–Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alpha-V beta-3/alpha-V beta-5 integrin Anaagonist.  Enantioselective synthesis and stereochemical studies” W. A. Kinney, C. A. Teleha, A. S. Thompson, M. Newport, R. Hansen, S. Ballentine, S. Ghosh, A. Mahan, G. Grasa, A. Zanotti-Gerosa, J. Dingenen, C. Schubert, Y. Zhou, G. C. Leo, D. F. McComsey, R. J. Santulli, B. E. Maryanoff, J. Org. Chem. 2008, 73, 2302-2310.
14. “Studies with an orally bioavailable alpha-V beta-3/alpha-V beta-5 integrin antagonist in animal models of ocular vasculopathy: Retinal neovascularization in mice and retinal vascular permeability in diabetic rats” R. J. Santulli, W. A. Kinney, S. Ghosh, B. L. DeCorte, L. Liu, R. W. A. Tuman, Z. Zhou, N. Huebert, S. E. Bursell, A. C. Clermont, M. B. Grant, L. C. Shaw, S. A. Mousa, R. A. Galemmo, Jr., D. L. Johnson, B. E. Maryanoff, B. P. Damiano, J. Pharmacol. Exp. Ther. 2008, 324, 894-901. 
15. “Thrombogenic collagen-mimetic peptides: self-assembly of triple helix-based fibrils driven by hydrophobic interactions” M. A. Cejas, W. A. Kinney, C. Chen, J. G. Vinter, H. R. Almond, Jr., K. M. Balss, C. A. Maryanoff, U. Schmidt, M. Breslav, A. Mahan, E. Lacy, C. Yang, B. E. Maryanoff,  Proc. Natl. Acad. Sci. USA 2008, 105, 8525-8530.
    

Muth Publications (Selected from 26)

1. "A method for the discrete removal of a segment of the dorsal noradrenergic bundle and its application to analysis of catecholamine and dopamine-beta-hydroxylase" D. M. Jacobowitz, M. F. Roizen, N. L. Suttora, E. A. Muth, Brain Res. 1975, 98, 377-382.
2. "Biochemical mapping of noradrenergic projections of axons in the dorsal noradrenergic bundle" M. F. Roizen, R. M. Kobayashi, E. A. Muth, D. M. Jacobowitz Brain Res. 1976, 104, 384-389.
3. "Effects of ovarian hormones on levels of luteinizing hormone in plasma and on serotonin concentrations in discrete brain nuclei" W. R. Crowley, T. L. O'Donohue, E. A. Muth, D. M. Jacobowitz, Brain Res., Bull. 1979, 4, 571-574.
4. "Effect of gonadal hormones on luteinizing hormone in plasma and on choline acetyltransferase activity and acetylcholine levels in discrete nuclei of the rat brain" E. A. Muth, W. R. Crowley, D. M. Jacobowitz,  Neuroendocrinology 1980, 30, 329-336.
5. "DMI, Wy-45,030, Wy-45,881, and ciramadol inhibit locus coeruleus neuronal activity" J. T. Haskins, J. A. Moyer, E. A. Muth, E. B. Sigg,  Eur. J. Pharmacol. 1985, 115: 139-146.
6. "Antidepressant biochemical profile of the novel bicyclic compound, Wy-45,030" E. A. Muth, J. T. Haskins, J. A. Moyer, G. E. M. Husbands, S. T. Nielsen, E. B. Sigg, Biochemical Pharmacology 1986, 35, 4493-7.
7. "Psychotropic agents:  Synthesis and antipsychotic activity of substituted beta-carbolines" M. Abou-Gharbia, U. Patel, J. A. Moyer, E. A. Muth, J. Med. Chem. 1987, 30, 1100-1105.
8. "Biochemical and electrophysiological studies of the psychotropic compound, amperozide" J. T. Haskins, E. A. Muth, T. H. Andree, Brain Res. Bull. 1987, 19, 465-71.
9. "Antipsychotic activity of substituted gamma-carbolines" M. Abou-Gharbia, U. Patel, M. Webb, J. A. Moyer, T. H. Andree, E. A. Muth J. Med. Chem. 1987, 30, 1818-23.
10. "Behavioral pharmacology of the gamma carboline Wy-47,384: A potential antipsychotic agent"  J. A. Moyer, M. Abou-Gharbia, E. A. Muth Eric A. Drug Devel. Res. 1988, 13, 11-28.
11. "Preclinical profile of the pyrimidinylpiperazinyl imide compound Wy-47,846:  A potential anxiolytic" J. T. Haskins,  J. A, Moyer, T. H. Andree, E. A. Muth, M. Abou-Gharbia, Drug Dev. Res. 1989, 18, 29-45.
12. "2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and antidepressant activity" J. P. Yardley, G. E. M. Husbands, G. Stack, J. Butch, J. Bicksler, J. A. Moyer, E. A. Muth, T. H. Andree, H. Fletcher, III, M. N. G. James,  A. R. Sielecki. J. Med. Chem. 1990, 33, 2899-2905.
13. "Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant, venlafaxine" E. A. Muth, J. A. Moyer, J. T. Haskins, T. H. Andree, G. E. M. Husbands, Drug Devel. Res. 1991, 23, 191-199.
14. "ECNP Meeting Report" E. A. Muth, M. Abou-Gharbia, Drug News Perspec. 1992, 5, 317-319.
15. "Venlafaxine:  A new dimension in antidepressant pharmacotherapy" S. A. Montgomery, J. P. Feighner, A. Frazer, G. Magni, E. A. Muth, J. Clin. Psychiat. 1993, 54, 119-126.